Hematologic Malignancy
Chronic Leukemia
CI-CAN-00000764Explore in graph →
Hematologic410 active trials10 approved drugs59 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000764Explore in graph →
Clinical trials
1,704 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (302)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00877214 | Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas(MAINTAIN) | unknown | Phase 3 | 1,272 | Jurgen BarthOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT04682808 | A Study of FCN-338 in Patients With Chronic CLL/SLL | unknown | Phase 1 | 99 | Fochon Pharmaceuticals, Ltd.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT00899223 |
| Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes |
| unknown |
| — |
| 1,500 |
| Alliance for Clinical Trials in OncologyOTHER |
| 1 |
| Jul 31, 2024 |
| clinicaltrials |
| NCT06489184 | The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China | unknown | — | 490 | Peking University People's HospitalOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT01346020 | Genomic Analysis of Patients With Chronic Lymphocytic Leukemia | unknown | — | 53 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT05371392 | Polymorphism of ITGA4 Gene in Chronic Lymphocytic Leukemia | unknown | — | 80 | Sohag UniversityOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT06379282 | Investigating the Role of Energy Balance Modification on Health Responses in Chronic Lymphocytic Leukaemia(HIT-CLL) | unknown | N/A | 132 | University of SurreyOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT03682029 | Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies(EVITA) | unknown | N/A | 109 | Rigshospitalet, DenmarkOTHER | 2 | Apr 17, 2024 | clinicaltrials |
| NCT06084923 | Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease Progression | unknown | — | 73 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | Apr 10, 2024 | clinicaltrials |
| NCT06335277 | Total Body Irradiation Treatments for Patients Treated at European Institute of Oncology | unknown | — | 50 | European Institute of OncologyOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT04358393 | A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS | unknown | Phase 1 / Phase 2 | 69 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT06233890 | The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia(TIRE) | unknown | — | 50 | Imperial College Healthcare NHS TrustOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT04663100 | Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence | unknown | N/A | 30 | University of TennesseeOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT05803395 | Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy. | unknown | — | 954 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT06121765 | Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI | unknown | — | 45 | Assiut UniversityOTHER | 0 | Nov 8, 2023 | clinicaltrials |
| NCT05959694 | A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . | unknown | Phase 1 / Phase 2 | 107 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT04754035 | Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia(IMPROVE) | unknown | Phase 2 | 31 | Paolo GhiaOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT02229422 | A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)(GA101 & HDMP) | unknown | Phase 1 / Phase 2 | 40 | University of California, San DiegoOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT05970822 | Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML | unknown | Phase 1 | 32 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05020392 | Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma | unknown | Phase 3 | 24 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 25, 2023 | clinicaltrials |
| NCT02825836 | Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects | unknown | Phase 1 / Phase 2 | 130 | Telios Pharma, Inc.INDUSTRY | 7 | Jul 13, 2023 | clinicaltrials |
| NCT05941156 | Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia | unknown | Phase 2 | 20 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05932173 | A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies | unknown | Phase 1 / Phase 2 | 60 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT04763083 | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies | unknown | Phase 1 | 90 | NovalGen Ltd.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05899543 | Determining Clinical Study Experiences of Chronic Lymphocytic Leukemia Patients | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Jun 12, 2023 | clinicaltrials |
| NCT04578613 | ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL | unknown | Phase 3 | 218 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jun 5, 2023 | clinicaltrials |
| NCT05888701 | "Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity. | unknown | — | 30 | University of Milano BicoccaOTHER | 1 | Jun 5, 2023 | clinicaltrials |
| NCT04923048 | A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL. | unknown | Phase 1 / Phase 2 | 460 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | May 22, 2023 | clinicaltrials |
| NCT05487651 | Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies(ANCHOR2) | unknown | Phase 1 | 36 | Athenex, Inc.INDUSTRY | 1 | May 18, 2023 | clinicaltrials |
| NCT05859932 | Assessing Medical Trial Experiences of Hairy Cell Leukemia Patients | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | May 16, 2023 | clinicaltrials |
| NCT03933852 | Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose(Ponderosa) | unknown | — | 100 | University of JenaOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT04356846 | A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma | unknown | Phase 1 | 74 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT03883087 | A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation | unknown | Phase 2 | 41 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT05739227 | Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies | unknown | Early Phase 1 | 12 | Xuzhou Medical UniversityOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT05360758 | Ibrutinib Adapted to Response in Patients With CLL | unknown | — | 80 | Grupo Argentino de Tratamiento de la Leucemia AgudaOTHER | 0 | Dec 28, 2022 | clinicaltrials |
| NCT05638763 | Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia | unknown | Phase 2 | 15 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT03280160 | Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab | unknown | Phase 2 | 84 | PETHEMA FoundationOTHER | 1 | Sep 16, 2022 | clinicaltrials |
| NCT05543161 | "Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a Diagnostic Marker" | unknown | — | 50 | Sohag UniversityOTHER | 1 | Sep 16, 2022 | clinicaltrials |
| NCT03226301 | A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations | unknown | Phase 2 | 230 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 6 | Aug 2, 2022 | clinicaltrials |
| NCT05311943 | Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs. | unknown | Phase 3 | 40 | Shenzhen Second People's HospitalOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05410041 | Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies | unknown | Phase 1 | 15 | Beijing Boren HospitalOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT05353205 | A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. | unknown | Phase 4 | 200 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05287984 | Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL(ZFCR/ZBR) | unknown | Phase 2 | 63 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT03942094 | Nilotinib for First-line Newly Diagnosed CML-CP Patients | unknown | Phase 3 | 100 | Shenzhen Second People's HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT04677439 | Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure | unknown | Phase 4 | 200 | Shenzhen Second People's HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT03529227 | Gazyva Infusion Reaction Investigation(GAIRI) | unknown | — | 104 | Healthy FutureOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT04640909 | Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients | unknown | N/A | 23 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT05145101 | Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukaemia(Pneumo-CLL) | unknown | — | 150 | Hannah Garcia GarridoOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT04616274 | Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia | unknown | — | 500 | National Taiwan University HospitalOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT04862806 | Safety, Efficacy of BNT162b2 mRNA Vaccine in CLL | unknown | N/A | 1,000 | Bnai Zion Medical CenterOTHER_GOV | 1 | Sep 17, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Aug 22, 2024source: clinicaltrials